Shares of Insmed (INSM) surged 12.01% in pre-market trading on Thursday, despite reporting disappointing third-quarter 2025 financial results. The biopharmaceutical company's stock rally appears to be driven by an optimistic full-year revenue outlook, overshadowing the quarterly performance.

Insmed reported a third-quarter net loss of $370 million, with earnings per share (EPS) of -$1.75. The company's revenue for the quarter came in at $28.1 million, significantly below the IBES estimate of $114.4 million. Despite these underwhelming figures, investors seem to be focusing on the company's forward-looking statements.

The key driver behind the stock's pre-market surge appears to be Insmed's full-year revenue outlook. The company projects fiscal year 2025 revenue to be in the range of $420-430 million. This positive guidance suggests that Insmed expects a substantial improvement in its performance in the coming quarters, which has evidently sparked investor optimism. The market's reaction indicates that traders are looking beyond the current quarter's results and betting on the company's future potential.